Literature DB >> 29863412

Capillary blood microsampling to determine serum biopharmaceutical concentration: Mitra® microsampler vs dried blood spot.

Karien Bloem1,2, Tiny Schaap2, Ronald Boshuizen2, Eva L Kneepkens3, Gerrit J Wolbink1,3, Annick de Vries2, Theo Rispens1.   

Abstract

AIM: For assessment of concentrations of biopharmaceuticals, for example, therapeutic drug monitoring, dried blood sampling of capillary blood is a convenient alternative to traditional venepuncture sampling. We investigated an alternative to dried blood spot collection on filter paper: sampling capillary blood using the Mitra® microsampler.
MATERIALS AND METHODS: Therapeutic monoclonal antibodies were spiked in whole blood, sampled using filter paper and Mitra microsampler and concentrations measured using specific ELISAs.
RESULTS: Good recoveries of adalimumab, infliximab, ustekinumab, vedolizumab, tocilizumab, natalizumab and rituximab were found up to 1 month of storage at room temperature, averaging 95.2% for the Mitra microsampler and 92.9% for Whatman® paper. Both hemoglobin and potassium yield satisfactory estimates for the volume of the cellular fraction of blood samples in combination with the Mitra microsampler.
CONCLUSION: We established practical protocols for the estimation of serum/plasma concentrations of therapeutic antibodies via capillary blood microsampling.

Entities:  

Keywords:  DBS; biologic; capillary blood microsampling; dried blood spot; therapeutic monoclonal antibody

Mesh:

Substances:

Year:  2018        PMID: 29863412     DOI: 10.4155/bio-2018-0010

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  5 in total

1.  Golimumab Dried Blood Spot Analysis (GOUDA): a Prospective Trial Showing Excellent Correlation with Venepuncture Samples and More Detailed Pharmacokinetic Information.

Authors:  Iris Detrez; Ganel Schops; Jolien Lefrère; Sophie Tops; Gert Van Assche; Séverine Vermeire; Wouter Van Moerkercke; Marc Ferrante; Ann Gils
Journal:  AAPS J       Date:  2018-12-18       Impact factor: 4.009

2.  Promising Tools to Facilitate the Implementation of TDM of Biologics in Clinical Practice.

Authors:  Rani Soenen; Christophe Stove; Alessio Capobianco; Hanne De Schutter; Marie Dobbelaere; Tahmina Mahjor; Merel Follens; Jo Lambert; Lynda Grine
Journal:  J Clin Med       Date:  2022-05-26       Impact factor: 4.964

3.  Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation.

Authors:  Sophie E Berends; Geert R A M D'Haens; Tiny Schaap; Annick de Vries; Theo Rispens; Karien Bloem; Ron A A Mathôt
Journal:  Br J Clin Pharmacol       Date:  2019-05-11       Impact factor: 4.335

4.  Clinical response correlates with 4-week postinjection ustekinumab concentrations in patients with moderate-to-severe psoriasis.

Authors:  N Van den Berghe; E De Keyser; R Soenen; L Meuleman; S Lanssens; A Gils; J Lambert
Journal:  Br J Dermatol       Date:  2019-07-24       Impact factor: 9.302

Review 5.  The Evolving Role of Microsampling in Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory Diseases.

Authors:  Panagiotis-Dimitrios Mingas; Jurij Zdovc; Iztok Grabnar; Tomaž Vovk
Journal:  Molecules       Date:  2021-03-22       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.